Physicochemical Properties
| Molecular Formula | C60H84N16O16 |
| Molecular Weight | 1285.40657329559 |
| Exact Mass | 1284.625 |
| CAS # | 1470374-22-1 |
| Related CAS # | TAK-448;1234319-68-6 |
| PubChem CID | 91668185 |
| Appearance | White to off-white solid powder |
| Hydrogen Bond Donor Count | 18 |
| Hydrogen Bond Acceptor Count | 17 |
| Rotatable Bond Count | 31 |
| Heavy Atom Count | 92 |
| Complexity | 2470 |
| Defined Atom Stereocenter Count | 10 |
| SMILES | O[C@H]1CN(C([C@@H](CC2C=CC(=CC=2)O)NC(C)=O)=O)[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NNC(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CC2=CNC3C=CC=CC2=3)=O)CCCN/C(=N/C)/N)=O)CC(C)C)=O)=O)CC2C=CC=CC=2)=O)[C@@H](C)O)=O)CC(N)=O)=O)C1.OC(C)=O |
| InChi Key | ITKNOAGWRWNSIK-NHDJLUSCSA-N |
| InChi Code | InChI=1S/C58H80N16O14.C2H4O2/c1-30(2)22-42(51(82)66-40(16-11-21-63-57(61)62-5)50(81)67-41(49(60)80)25-35-28-64-39-15-10-9-14-38(35)39)70-58(88)73-72-53(84)43(23-33-12-7-6-8-13-33)69-55(86)48(31(3)75)71-52(83)44(27-47(59)79)68-54(85)46-26-37(78)29-74(46)56(87)45(65-32(4)76)24-34-17-19-36(77)20-18-34;1-2(3)4/h6-10,12-15,17-20,28,30-31,37,40-46,48,64,75,77-78H,11,16,21-27,29H2,1-5H3,(H2,59,79)(H2,60,80)(H,65,76)(H,66,82)(H,67,81)(H,68,85)(H,69,86)(H,71,83)(H,72,84)(H3,61,62,63)(H2,70,73,88);1H3,(H,3,4)/t31-,37-,40+,41+,42+,43+,44+,45-,46+,48+;/m1./s1 |
| Chemical Name | (2S)-2-[[(2S,4R)-1-[(2R)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-N-[(2S,3R)-1-[[(2S)-1-[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-[(N'-methylcarbamimidoyl)amino]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]hydrazinyl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]butanediamide;acetic acid |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vivo | In the VCaP xenograft model, TAK-448 acetate salt (0.01-3 mg/kg; ih medication; day 0 and day 28 drug) exhibits more potent anti-tumor actions [2]. |
| Animal Protocol |
Animal/Disease Models: Rat VCaP xenograft androgen-sensitive prostate cancer model (7weeks old rats) Doses: 0.01, 0.03, 0.3, 3 mg/kg Route of Administration: administered every other day; administered on days 0 and 28 Drug Experimental Results: Greater anti-tumor effect in VCaP xenograft model. |
| References |
[1]. Design and Synthesis of an Investigational Nonapeptide KISS1 Receptor (KISS1R) Agonist, Ac-d-Tyr-Hydroxyproline (Hyp)-Asn-Thr-Phe-azaGly-Leu-Arg(Me)-Trp-NH2 (TAK-448), with Highly PotentTestosterone-Suppressive Activity and Excellent Water Solubility. J Med Chem. 2016 Oct 13;59(19):8804-8811. [2]. Usefulness of pharmacokinetic/efficacy analysis of an investigational kisspeptin analog, TAK-448, in quantitatively evaluating anti-tumor growth effect in the rat VCaP androgen-sensitiveprostate cancer model. Eur J Pharmacol. 2018 Jun 5;828:126-134. |
Solubility Data
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~77.80 mM) H2O : ~50 mg/mL (~38.90 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (1.94 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (1.94 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: 100 mg/mL (77.80 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7780 mL | 3.8898 mL | 7.7796 mL | |
| 5 mM | 0.1556 mL | 0.7780 mL | 1.5559 mL | |
| 10 mM | 0.0778 mL | 0.3890 mL | 0.7780 mL |